Consensus Galapagos NV Sao Paulo

Stocks

G1LP34

BRG1LPBDR002

Biotechnology & Medical Research

Market Closed - Sao Paulo 11:26:48 2026-10-21 EDT			5-day change	1st Jan Change
7.710 ^BRL	-0.77%		+5.47%	-16.01%

10-15	Lakefront Biotherapeutics Closes Sale of Early-stage Cell Therapy Assets	MT
10-14	Lakefront Biotherapeutics Sells Preclinical CAR-T Programs to Armed Cell Therapeutics	MT

e.gL4bAuL2KTet4_4L4NgtS63qI8lyIoRfvyYZpaNlnrQ.-e9TTpKGdlDEpop8kpZheMSGdYQAD8My5Uhbz9oN1sL01HpJgadmA8aLyg~c7324c863668b2e571f01181903fa498

Analysts' recommendations: Galapagos NV

09-23	Lakefront Biotherapeutics' Gamgertamig Has Meaningful Opportunity in Rare Autoimmune Diseases, RBC Says	MT
09-23	RBC Upgrades Lakefront Biotherapeutics to Outperform From Sector Perform, Adds Speculative Risk, Raises Price Target to $45 From $26	MT
08-11	RBC Adjusts PT on Lakefront Biotherapeutics to $26 From $28, Keeps Sector Perform Rating	MT
08-11	Morgan Stanley Adjusts PT on Lakefront Biotherapeutics to $26 From $30, Maintains Equalweight Rating	MT
04-07	RBC Adjusts Price Target on Galapagos NV to $28 From $33, Maintains Sector Perform Rating	MT
02-25	RBC Capital Adjusts Galapagos NV PT to $33 From $32, Maintains Sector Perform Rating	MT
11-26	Bernstein Starts Galapagos at Market-perform, Says 'Unique in the Healthcare Space'	MT
11-07	RBC Adjusts Price Target on Galapagos to $32 From $28, Maintains Sector Perform Rating	MT
25-10-22	RBC Raises Price Target on Galapagos to $28 From $27, Keeps Sector Perform Rating	MT
25-04-25	RBC Cuts Price Target on Galapagos to $27 From $32, Keeps Sector Perform Rating	MT
25-02-14	Morgan Stanley Downgrades Galapagos to Underweight From Equal Weight, Adjusts Price Target to $22 From $31	MT
24-09-09	Leerink Partners Initiates Coverage on Galapagos NV With Market Perform Rating, $24 Price Target	MT
24-03-28	Galapagos Continues to be 'Value Trap' With Unclear Growth Path, BofA Says	MT
24-03-28	BofA Securities Downgrades Galapagos to Underperform From Neutral, Says 'Stock Remains a Value Trap'; Adjusts Price Target to $31 From $41	MT
23-12-05	JPMorgan Cuts Galapagos Price Target to $37 From $45, Maintains Neutral Rating	MT
23-08-07	Morgan Stanley Adjusts Galapagos' Price Target to $40 From $42, Keeps Equalweight Rating	MT
23-08-07	RBC Cuts Price Target on Galapagos to $38 From $41, Keeps Sector Perform Rating	MT
23-05-31	JPMorgan Lowers Price Target on Galapagos to $45 From $52, Maintains Neutral Rating	MT
23-05-09	Morgan Stanley Adjusts Price Target on Galapagos to $42 From $44, Keeps Equalweight Rating	MT
23-05-08	Raymond James Upgrades Galapagos to Outperform From Market Perform, Price Target is $69	MT
23-05-08	RBC Cuts Price Target on Galapagos to $41 From $43 Amid 'Slowed Adoption' of Jyseleca, Maintains Sector Perform Rating	MT
23-02-27	Morgan Stanley Adjusts Price Target on Galapagos to $44 From $57, Maintains Equal-Weight Rating	MT
23-02-27	RBC Cuts Price Target on Galapagos to $43 From $53, Maintains Sector Perform Rating	MT
23-01-23	Jefferies Upgrades Galapagos to Hold From Underperform, Adjusts Price Target to $47.20 From $49	MT
22-11-07	RBC Lowers Price Target on Galapagos to $53 From $55, Keeps Sector Perform Rating	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	WUXI APPTEC CO., LTD.					+32.59%
	ARGENX SE					+28.09%
	LONZA GROUP AG					+10.26%
	IQVIA HOLDINGS INC.					+8.34%
	BEONE MEDICINES AG					+15.58%
	REVOLUTION MEDICINES, INC.					+38.43%
	CELLTRION, INC.					+38.53%
	GENMAB A/S					+4.99%
	WUXI BIOLOGICS (CAYMAN) INC.					+31.23%
	Average					+23.11%
	Weighted average by Cap.					+23.35%